VANCOUVER, British Columbia, April 17, 2023 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) is pleased to announce that it has hired to Maxim Group LLC (“Maxim”), headquartered in New York City, as its financial advisor and investment banker to provide general financial advisory and investment banking services, including strategic planning, evaluation of potential strategic alliances and capital requirements, and advising the Company regarding the process of obtaining a listing on a US national stock exchange.
In consideration of their commitment and prior service provided by Maxim, BioVaxys has agreed to issue Maxim 2,902,236 common shares, subject to Canadian Stock Exchange approval. Common shares issued to Maxim will be subject to a statutory restriction period of four months one day.
James Passin, CEO of BioVaxys, stated: “We look forward to working with Maxim Group to enhance shareholder value and unlock potentially transformative capital market opportunities.”
About Maxim Group LLC
Founded in 2002, Maxim Group is a leading midtown Manhattan-based full-service investment banking, securities and wealth management firm offering a broad range of financial services including investment banking, global institutional sales, investment research, equities, fixed income and derivative sales and trading, business capital, private wealth management and prime brokerage services for a wide range of corporate clients, institutional investors and high net worth individuals. Maxim Group is a registered broker-dealer with the US Securities and Exchange Commission and the Municipal Securities Regulation Board (MSRB).
About BioVaxys Technology Corp.
Headquartered in Vancouver, BioVaxys Technology Corp. (www.biovaxys.com) is a British Columbia-registered clinical-stage biotechnology company developing platforms for viral and oncology vaccines, as well as immunodiagnostics. The Company is advancing vaccines for SARS-CoV-2, SARS-CoV-1, and a sarbecovirus vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its used haptenized autologous cell vaccine. in combination with anti-PD1 and anti-PDL1 checkpoint inhibitors to be initially developed for stage III/stage IV ovarian cancer. Also in development is CoviDTH®, a diagnostic to assess the presence or absence of a T-cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued US patents and multiple US and international patent applications related to its cancer vaccines, antiviral vaccines and diagnostic technologies. BioVaxys common shares are listed on the CSE under the ticker symbol “BIOV” and are traded on the Frankfurt Stock Exchange (FRA: 5LB) and in the US (OTCQB: BVAXF).
Signed “James Passin”
James Passin, CEO 1 646 452 7054
Cautionary Notes Regarding Forward-Looking Information
This press release includes certain “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable Canadian and United States securities law, including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, statements herein relating to the Company’s future operating or financial performance, are forward-looking statements. Forward-looking statements are often, but not always, identified by words such as “expects,” “anticipates,” “believes,” “intends,” “estimates,” “potential,” “possible,” and similar expressions or statements that the events, conditions or results “will”, “may”, “could” or “should” occur or be achieved. Forward-looking statements in this press release relate to, among other things, a possible listing of the Company on a US national stock exchange or the completion of a capital markets transaction. No guarantee can be made that such statements will be accurate, and actual results and future events could differ materially from those expressed or implied by such forward-looking statements.
These forward-looking statements reflect the beliefs, opinions and projections as of the date the statements are made and are based on a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in obtaining a listing on a US national stock exchange. U.S. or complete a capital market transaction. There are numerous risks that could affect BioVaxys’ ability to obtain such a listing and complete a capital market transaction, including, but not limited to, the market price of the Company’s common shares, cash flow and income of the Company. and global economic factors in general. With respect to BioVaxys’ business, there are a number of risks that could affect the development of its biotech products, including, but not limited to, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty as to whether its products will complete the lengthy, complex and costly clinical trial and regulatory approval process for new drug approvals required for marketing approval, uncertainty about whether their cell autologous vaccine immunotherapy can be developed to produce safe and effective products and, if If so, if their vaccine products are to be commercially accepted and profitable, the expenses, delays and uncertainties and complications that development-stage biopharmaceutical companies often face, financial and development obligations under license agreements to protect their rights about its products and technologies, obtain and protect new intellectual property rights, and prevent third-party infringement and your reliance on third-party manufacturing.
The Company does not undertake any obligation to update forward-looking statements of beliefs, opinions, projections or other factors, should they change, except as required by law.
Logo – https://mma.prnewswire.com/media/1430981…
View original content: https://www.prnewswire.com/news-releases/biovaxys-conserva-a-maxim-group-como-asesor-financiero-y-banquero-de-inversion-301798618.html
